Bioinformatics Analysis Reveals That CBX2 Promotes Enzalutamide Resistance in Prostate Cancer

Silencing of CBX2 using small interfering RNA led to elevated levels of P53 expression in LNCaP cells. This indicated that CBX2 may have a critical effect on prostate cancer Enz resistance and could serve as a promising therapeutic target for individuals with Enz resistance.